Phase3 study of T-1220 in the patients with bacterial infectious disease-Open label, multi-center study
Phase 3
- Conditions
- Sepsis, Acute bronchitis, Pneumonia, Lung abscess, Pyothorax, Secondarinfection of chronic respiratory disease, Cystitis, Pyelonephritis, Cholecystitis, Cholangitis, Bartholinitis, Intrauterine infection, Uterine adnexitis, Parametritis, Purulent meningitisy
- Registration Number
- JPRN-jRCT2080221672
- Lead Sponsor
- Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1)Sex:male or female
(2)Age: 20 years and older for adult and 28 days to 16 years old (inclusive) for child
(3)Outpatient or inpatient: inpatient
(4)Presence of definite symptom/findings of infectious disease
(5)Others
Exclusion Criteria
(1)Medical history of allergy to any beta-lactam antibacterial agents.
(2)Patient with infectious mononucleosis.
(3)Pregnant females, females wishing to become pregnant or being possibly pregnant, and lactating females.
(4)Others.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety<br>Same as above
- Secondary Outcome Measures
Name Time Method